Views
5 years ago

104 - D Pobihuszka

  • Text
  • Pobihuszka
  • Pobihuszka
  • Glutamato
  • Network
  • Emocional
  • Depresion
  • Alucinogenos
  • Psilocibina
  • Pacientes
  • Dosis
  • Ansiedad
  • Estudios
  • Receptor
  • Efecto
Alucinógenos serotoninérgicos: posibles implicancias en el tratamiento de depresión y trastornos por ansiedad - Damián Pobihuszka

Dr. Damián

Dr. Damián Pobihuszka Psychopharmacol. Jun;28(6):545-52. • Buckner RL, Andrews-Hanna JR, Schacter DL. (2008). The brain’s default network: anatomy, function, and relevance to disease. Ann. N. Y. Acad. Sci. 1124:1–38. • Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH1, Nutt DJ. (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. May 16. pii: S2215- 0366(16)30065-7. • Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, Tyacke RJ, Leech R, Malizia AL, Murphy K, Hobden P, Evans J, Feilding A, Wise RG, Nutt DJ. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A.Feb 7;109(6):2138-43. • Carstairs SD and Cantrell FL. (2010). Peyote and mescaline exposures: a 12-year review of a statewide poison center database. Clin Toxicol (Phila). 48:350–353. • Catlow, B., Song, S., Paredes, D., Kirstein, C. and Sanchez-Ramos, J. (2013). Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res.; 228: 481–491. • Clark, L., Chamberlain, S. R. & Sahakian, B. J. (2009). Neurocognitive mechanisms in depression:implications for treatment. Annu. Rev. Neurosci32,57–74. • Dantzer, R., O’Connor, J., Freund, G., Johnson, R. and Kelley, K. (2008). From inflammation to sickness and depression: when the immune system subjugatesthe brain. Nat Rev Neurosci. 9: 46–56. • DeRubeis, R. J., Siegle, G. J. & Hollon, S. D. (2008). Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms. Nature Rev.Neurosci. 9, 788–796. Disner SG, Beevers CG, Haigh EA, Beck AT. (2011). Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci. 12(8):467–477. • Doblin, R. (1991). Pahnke's 'Good Friday Experiment: A Long-Term Follow-Up and Methodological Critique. Florida: New College of Florida-J. of Transp. Psych. 23 (1) 1-28. • Fantegrossi WE, Murnane KS, Reissig CJ. (2008). The behavioral pharmacology of hallucinogens. Biochem Pharmacology. 75(1):17–33. Fantegrossi WE, Woods JH, Winger G. (2004).Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behav Pharmacol.15(2):149–57. • Frokjaer, V. G. et al. (2008). Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol. Psychiatry. 63, 569–576. • Fu, C. H. et al. (2004). Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch. Gen. Psychiatry. 61, 877–889. • Gable, R.S. (2007). Risk assessment of ritual use of oraldimethyltryptamine (DMT) and harmala alkaloids. Addiction.;102(1), 24–34. • Gasser P, Kirchner K, Passie T. (2015). LSD-assisted psychotherapy for anxietyassociated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol. 29:57–68. • Gasser P, Holstein D, Michel Y, et al. (2014). Safety and efficacy of LSD-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 202-513–520. • Gewirtz, J.C., Chen, A.C., Terwilliger, R., Duman, R.C., Marek, G.J. (2002). Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors. Pharmacol. Biochem. Behav. 73, 317–326. • González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF,Zhou M, Okawa Y, Callado LF, and Milligan G, et al. (2008). Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature. 452:93–97. • Gouzoulis-Mayfrank, E. et al. (1999). Neurometabolic effects of psilocybin, 3,4 methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with[18F]FDG. Neuropsychopharmacology. 20, 565–581. • Gresch, P. J., Smith, R. L., Barrett, R. J. & Sanders- Bush, E. (2005). Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex. Neuropsychopharmacology .30, 1693–1702. • Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA. J. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Psychopharmacol.Dec; 30(12):1181-1197. • Griffiths RR, Richards WA, McCann U, Jesse R. (2006). Psilocybin can occasion mysticaltype experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 187(3):268-283. • Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, and Greer GR. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 68:71–78. • Grob CS, McKenna DJ, Callaway JC, Brito GS, Neves ES, Oberlaender G, Saide OL, Labigalini E, Tacla C, and Miranda CT, et al. (1996). Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment. Dis.184:86–94. • Grof S. (1980). LSD Psychotherapy. Hunter House, Pomona, CA. • Halberstadt AL. (2015). Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res. 277:99–120. • Halpern JH and Pope HG Jr. (1999). Do hallucinogens cause residual neuropsychological toxicity? Drug Alcohol Depend. 53:247–256. • Halpern JH and Pope HG Jr. (2003). Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend. 69:109–119. • Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. (2004). Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl). Mar;172(2):145-56. • Hoffer, A. (1970) in The Uses and Implications of Hallucinogenic Drugs (eds Aaronson, B. & Osmond, H.). p357–366. Hogarth Press, London. • Johansen PO and Krebs TS. (2015). Psychedelics not linked to mental health problems or suicidal behavior: a population study. J Psychopharmacol (Oxf) Sep; 29(9):1036-40. • Johnson MW, Sewell RA, and Griffiths RR. (2012). Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend. 123:132–140. • Kaumann AJ and Levy FO. (2006).5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther.111:674–706. • Klock JC, Boerner U, and Becker CE. (1974). Coma, hyperthermia and bleeding associated with massive LSD overdose. A report of eight cases. West J Med. 120:183– 188. • Kometer M, Pokorny T, Seifritz E, Volleinweider FX. (2015). Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations. Psychopharmacology (Berl). Oct;232(19):3663-76. • Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, and Vollenweider FX. (2012). Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry. 72:898–906. • Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, and Vollenweider FX. (2015). Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry. 78:572–581. • Krebs TS and Johansen PO. (2013). Psychedelics and mental health: a population study. PLoS One. 8:e63972. • Krebs-Thomson K, Ruiz EM, Masten V, Buell M, Geyer MA. (2006). The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats. Psychopharmacology. 189:319– 329. • Levitt, R, Nason, E, Hallsworth, M. (2006). The Rand Corporation. The evidence base for the classification of drugs. 49-50. • Lüscher, C. and Ungless, M.A. (2006). TheMechanistic Classification of Addictive Drugs. PLoS Med. 3: e437. • Maeng, S. et al. (2008). Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3- hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry. 63, 349–352. • Massé F, Petit-Demouliere B, Dubois I, Hascoët M, and Bourin M. (2008). Anxiolyticlike effects of DOI microinjections into the hippocampus (but not the amygdala northe PAG) in the mice four plates test. Behav Brain Res. 188:291–297. • Massé F, Hascoët M, and Bourin M. (2007). Effect of GABAergic ligands on the anxiolytic-like activity of DOI (a 5-HT(2A/2C) agonist) in the four-plate test in mice. Eur Neuropsychopharmacol. 17:483–491. • Moghaddam, B. et al. (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17, 2921–2927. • Naranjo C. (2012). Ayahuasca, la enredadera del río celestial. Ed La Llave. • Nic Dhonnchadha BA, Hascoët M, Jolliet P, and Bourin M. (2003). Evidence for a 5-HT2A receptor mode of action in the anxiolytic-like properties of DOI in mice. Behav Brain Res. 147:175–184. • Nichols DE. (2016). Psychodelics. Pharmacological Reviews. 68:264-355. • Nichols DE. (2004). Hallucinogens. Pharmacol Ther.01(2):131–181. • Nielen, R.J., van der Heijden, F.M., Tuinier, S., Verhoeven, W.M. (2004).Khat and mushrooms associated with psychosis. World J. Biol. Psychiatr.5, 49–53. • Osorio FL, Sanches RF, Macedo LR, Dos Santos RG, Maia-de-Oliveira JP, Wichert-Ana L, de Araujo DB, Riba J, Crippa JA, and Hallak JE. (2015) Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: a Preliminary Report. Rev Bras Psiquiatr37:13–20. • Outhred T, Hawkshead BE, Wager TD, Das P, Malhi GS, Kemp AH. (2013). Acute neural effects of selective serotonin reuptake inhibitors versus noradrenaline reuptake inhibitors on emotion processing: Implications for differential treatment efficacy. Neurosci Biobehav. 37: 1786– 1800. • Panlab/ Harvard Apparatus [internet] Julio 2016. Disponible en www.panlab.com Pahnke WN. (1969) The psychedelic mystical experience in the human encounter with death. Harvard Theol Rev. 62(1):1-21. • Passie T, Halpern JH, Stichtenoth DO, Emrich HM, and Hintzen A. (2008). The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 14: 295– 314. • Phelps, L. E. et al. (2009). Family history of alcohol dependence and initial antidepressant response to an N- methyl-D-aspartate antagonist. Biol. Psychiatry. 65, 181–184. • Preller K, Pokorny T, Hock A, Kraehenmann R, Stämpfli P, Seifritz E, Scheidegger M, Vollenweider FX. (2016). Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. Proc Natl Acad Sci USA.; May 3;113(18):5119-24. • Pringle A, Browning M, Cowen PJ, Harmer CJ. (2011). A cognitive neuropsychological model of antidepressant drug action. Prog. Neuropsychopharmacol. Biol. Psychiatry. 35:1586–1592. • Puig, M. V., Celada, P., az-Mataix, L. & Artigas, F. (2003). In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents. Cereb. Cortex. 13, 870–882. • Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. (2001). A default mode of brain function. Proc. Natl. Acad. Sci. USA. 98:676–82. • Ripoll N, Hascoët M, and Bourin M. (2006). Implication of 5-HT2A subtype receptors in DOI activity in the four-plates test-retest paradigm in mice. Behav Brain Res. 166:131–139. • Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. Dec;30(12):1165-1180. • Ross S. (2012). Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatr Clin North Am. 35(2):357-74. • Salvadore, G. et al. (2010). Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology. 35, 1415–1422. • Sanacora G, Zarate C, Krystal J, Manji HK. (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. May;7(5):426-37. • Sen, S., Duman, R. and Sanacora, G. (2008). Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 64: 527–532. • Sessa B. (2005). Can psychedelics have a role in psychiatry once again? Br J Psychiatry. 186:457–458. Sheline, Y. I. et al. (2001). Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol. Psychiatry. 50, 651–658. • Shelton, R. C., Sanders-Bush, E., Manier, D. H. & Lewis, D. A. (2008). Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase, A.Neuroscience. 158, 1406–1415. • Sibille, E. et al. (1997). Antisense inhibition of 5- hydroxytryptamine2a receptor induces an antidepressantlike effect in mice. Mol. Pharmacol. 52, 1056–1063. • Speth J, Speth C, Kaelen M, Schloerscheidt AM, Feilding A, Nutt DJ, Carhart-Harris RL. (2016). Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide. J Psychopharmacol. Apr;30(4):344-53. • Surguladze, S. et al. (2005). A differential pattern of neural response toward sad versus happy facial expressions in major depressive disorder. Biol. Psychiatry. 57,201–209. • Suzuki J, Dekker MA, Valenti ES, Arbelo Cruz FA, Correa AM, Poklis JL, and Poklis A. (2015). Toxicities associated with NBOMe ingestion-a novel class of potent hallucinogens: a review of the literature. Psychosomatics. 56:129–139. • Szmulewicz AG, Valerio MP, Smith JM. (2015). Switch to mania after ayahuasca consumption in a man with bipolar disorder: a case report Int J Bipolar Disord.Feb 24;3:4. • Tittarelli R, Mannocchi G, Pantano F, Romolo FS. (2015). Recreational use, analysis and toxicity of tryptamines. Curr Neuropharmacol.13(1):26-46. • Tupper K, Wood E, Yensen R, Johnson M. (2015). Psychedelic medicine: a re-emerging therapeutic paradigm. CMAJ DOI:10.1503 /cmaj.141124. • Weisstaub, N. V. et al. (2006). Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice.Science. 313, 536–540. van Amsterdam J, Opperhuizen A, van den Brink W. (2011). Harm potential of magic mushroom use: a review. Regul Toxicol Pharmacol. 59(3):423-9. • van Reekum, C. M. et al. (2007). Individual differences in amygdala and ventromedial prefrontal cortex activity are associated with evaluation speed and psychological well-being. J. Cogn. Neurosci. 19, 237–248. • Vollenweider FX and Kometer M. (2010). The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosc. 11:642–651. • Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 9:3897–3902. • Vollenweider, F. X. et al. (1997). Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET)and[F-18]-fluorodeoxyglocose(FDG). Eur. Neuropsychopharmacol. 7, 9–24. • Walter, M. et al. (2009). The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. Arch. Gen. Psychiatry. 66, 478–486. • Whitfield-Gabrieli S, Judith F. (2012). Default mode network activity and connectivity in psychopathology. Annu Rev Clin Psychol. 8:49–76. • Yu, B., Becnel, J., Zerfaoui, M., Rohatgi, R., Boulares, A. and Nichols, C. (2008). Serotonin 5-hydroxytryptamine(2A) receptor activationsuppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency. J Pharmacol Exp Ther.327: 316–323. • Zarate, C. A. Jr et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatmentresistant major depression. Arch. Gen. Psychiatry. 63, 856–864. • Zhang, C. & Marek, G. J. (2007) AMPA receptor involvement in 5 hydroxytryptamine 2A receptor-mediated prefrontal cortical excitatory synaptic currents and DOI induced head shakes. Prog. Neuropsychopharmacol.Biol. Psychiatry.32, 62–71. 18 // EDITORIAL SCIENS

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015